Binge Eating Disorder Clinical Trial
Official title:
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
Verified date | October 2016 |
Source | Ottawa Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
Binge Eating Disorder (BED) affects as many as 3% of women and men in Ontario, 8% of obese individuals, and 30% to 50% of those participating in weight loss programs. BED, the most common eating disorder, is characterized by over-eating with loss of control (i.e., binge eating), but with no purging (e.g., vomiting).Our previous research indicates that the total health care costs for women with BED is 36% higher than the Canadian average for women of a similar age, and that health care costs significantly decreased following intensive treatment at our Centre. The main goal of our study is to inform the development of a stepped care approach to the treatment of BED. Stepped care involves providing easily accessible low intensity treatment first, and then providing more expensive intensive treatment second, if necessary. The second goal is to assess if a second more intensive step of treatment provides added value. Although stepped care for BED is suggested by a number of clinicians and researchers, no study adequately tests predictors of who might benefit from minimal treatment alone and who would require the more intensive second step. The results of this study will guide decision making regarding who benefits from stepped care, and will help to increase the accessibility, availability, and cost effectiveness of psychological treatments for BED.
Status | Active, not recruiting |
Enrollment | 150 |
Est. completion date | September 2017 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participants will be included if they: 1. are comfortable speaking or reading English; 2. do not have a history of an eating disorder other than BED, or a history of significant purging behaviour; 3. do not have a concurrent DSM-IV diagnosis of bipolar disorder, psychosis, drug or alcohol dependence; 4. are not currently or planning to be enrolled in a weight-loss program within the next year; 5. are women who are not pregnant or planning to be pregnant within the next year; and 6. are not currently or planning to be enrolled in other psychotherapies within the next year Exclusion Criteria: - Participants will be excluded if they: 1. are not comfortable speaking or reading English; 2. have a history of an eating disorder other than BED, or a history of significant purging behaviour; 3. have a concurrent DSM-IV diagnosis of bipolar disorder, psychosis, drug or alcohol dependence; 4. are currently or plan to be enrolled in a weight-loss program within the next year; 5. are women who are pregnant or planning to be pregnant within the next year; and 6. are currently or plan to be enrolled in other psychotherapies within the next year |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Regional Centre for the Treatment of Eating Disorders | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute | Ontario Mental Health Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Binge Eating Episodes in the Past 28 Days. | Binge eating is assessed in a structured interview using a calendar recall method (Wilfley et al., 1993). | Up to one and a half years | No |
Secondary | Body Mass Index (BMI). | This outcome variable will be calculated by dividing weight (kg) by height (m2). | Up to one and a half years | No |
Secondary | Center for Epidemiologic Studies Depression Scale (CES-D) | The CES-D is a brief self-report measure of depressive symptoms. | Up to one and a half years | No |
Secondary | Experiences in Close Relationships Scale (ECR) | The ECR, a predictor of USH outcome, is a 36-item measure comprising two 18-item scales (Avoidance and Anxiety). Items are scored on a 7-point Likert scale, ranging from 1 = Disagree Strongly to 7 = Agree Strongly. | Up to one and a half years | No |
Secondary | Inventory of Interpersonal Problems (IIP-64) | The IIP-64 assesses interpersonal problems; higher scores indicate greater problems. The IIP is a 64-item scale with a 5-point Likert-type response format. | Up to one and a half years | No |
Secondary | Patient Health Questionnaire 9 (PHQ-9). | The PHQ-9 is a 9-item self-report measure. The PHQ-9 is used in assessing the severity of depressive symptomology and can act as a diagnostic tool (Kroenke et al., 2001). | Up to one and a half years | No |
Secondary | Rapid Response to Treatment: Self-Monitoring | Self monitoring of binge eating is an indicator of rapid response to USH, which is a predictor of USH outcome. Daily record sheets will be used to assess objective binge eating episodes on an on-going basis throughout the course of USH. In each daily record, participants record whether they had any overeating behaviors (including objective binge episodes) and how many. The daily record forms provide a definition of objective binge episodes based on the EDE definition. These definitions will be reviewed with participants at the start of USH. | From the date of the start of unguided self-help to the end of self-help (Up to 10 weeks) | No |
Secondary | Rosenberg Self Esteem Scale (RSES) | The RSES, a predictor of USH outcome and an outcome variable, will be used to measure self esteem. The RSES is a ten-item self-report scale using a four-point response format. Scores are summed to produce a total score ranging from 0 to 30, with higher scores representing higher self esteem. | Up to one and a half years | No |
Secondary | Eating Disorder Diagnostic Scale (EDDS) | This is a self report measure of eating disorder symptoms including binge eating | From the start of Group Psychodynamic Interpersonal Psychotherapy (GPIP) to the end of GPIP (Up to 16 weeks) | No |
Secondary | Experiences in Close Relationships Scale Short Form (ECR-S). | The ECR-S, a predictor of USH outcome, is a 12-item measure comprising two 6-item scales (Avoidance and Anxiety). Items are scored on a 7-point Likert scale, ranging from 1 = Disagree Strongly to 7 = Agree Strongly. The ECR-S was derived from the full ECR scale which was derived from existing self-report adult romantic attachment measures. | From the start of Group Psychodynamic Interpersonal Psychotherapy (GPIP) to the end of GPIP (Up to 16 weeks) | No |
Secondary | Therapeutic Factors Inventory (TFI) | The full 99-item TFI will not be used in its entirety but rather the 9-item subscale of cohesiveness will only be used to measure levels of group cohesion throughout GPIP. It is a 7-point Likert-type scale with responses ranging from 1 (Strongly Disagree) to 7 (Strongly Agree). | From the start of Group Psychodynamic Interpersonal Psychotherapy (GPIP) to the end of GPIP (Up to 16 weeks) | No |
Secondary | Outcome Rating Scale (ORS) | The ORS was originally developed as a shorter form of the Outcome Questionnaire 45.2 (Miller et al., 2003). The ORS is a 4-item self-report scale that will be used as a treatment outcome measure of GPIP. | From the start of Group Psychodynamic Interpersonal Psychotherapy (GPIP) to the end of GPIP (Up to 16 weeks) | No |
Secondary | Working Alliance Inventory Short (WAI-S). | The WAI is a 12-item self-report measure of alliance to therapist and in this case the GPIP therapist. | From the start of Group Psychodynamic Interpersonal Psychotherapy (GPIP) to the end of GPIP (Up to16 weeks) | No |
Secondary | Eating Disorder Examination - Questionnaire (EDE-Q) | The EDE-Q, an outcome scale, is a 28-item self-report measure modeled on the EDE interview (Fairburn & Cooper, 1993). The EDE-Q Restraint scale measures dietary restraint, Eating Concern scale measures concern about eating, Shape Concern scale measures preoccupation with one's body shape, and Weight Concern scale measures preoccupation with one's body weight (Fairburn & Beglin, 1994)). The EDE-Q also provides a single overall score of eating disorder psychopathology based on the scales. | Up to one and a half years | No |
Secondary | Depression Anxiety and Stress Scales 21(DASS-21) | The DASS-21 is a self-report measure of stress, anxiety, and depression. | Up to one and a half years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 | |
Completed |
NCT00032760 -
Meditation-Based Treatment for Binge Eating Disorder
|
Phase 2/Phase 3 |